Key Information for Investors in Agenus Inc.
If you’re an investor in Agenus Inc. (NASDAQ: AGEN), there’s important news about a securities class action that you need to be aware of. If you purchased shares between January 23, 2023, and July 17, 2024, mark November 5, 2024, on your calendar. This is the lead plaintiff deadline for the class action.
Why This Is Important
This represents a crucial opportunity for investors who may qualify for compensation. The Rosen Law Firm, known for its dedication to safeguarding investor rights, is reminding affected shareholders about their options. If you bought shares during the mentioned period, it’s vital to know your rights and the potential benefits available to you.
What You Need to Know About the Class Action
A class action lawsuit has already been filed against Agenus Inc. If you think you were misled about the potential of Agenus' therapies, acting swiftly is essential. You might be able to claim compensation without facing direct legal fees, thanks to a contingency fee arrangement.
Steps to Take Now
If you want to be part of the class action, you can reach out to the firm directly or file a notice through the appropriate channels to join this important case. Taking proactive action is crucial, as participating could bring you significant benefits.
Why Choose the Rosen Law Firm?
The Rosen Law Firm is prominent in the area of securities class actions. With a reputation built on successful recoveries for shareholders, they consistently rank among the top firms for settlements. They have years of experience, having achieved hundreds of millions of dollars in recoveries for investors. Notably, they have also secured one of the largest settlements ever against a Chinese company.
Proven Success and Experience
In 2019 alone, the Rosen Law Firm recovered over $438 million for investors, demonstrating their strong track record. If you’re looking for representation, it’s wise to go with a law firm that has a solid reputation and expertise in class action lawsuits.
Case Details
The allegations in this lawsuit highlight misleading or false statements made by Agenus regarding their drug therapies. The company allegedly exaggerated the effectiveness and potential of treatments involving botensilimab and balstilimab. As these facts came to light, investors experienced losses, leading to the current legal action.
Contacting the Rosen Law Firm
If you need more information or wish to discuss your role in the lawsuit, feel free to contact the Rosen Law Firm. They have a direct line for inquiries and can assist you in understanding your rights as a shareholder.
Frequently Asked Questions
What’s the deadline to join the Agenus class action?
The lead plaintiff deadline is November 5, 2024.
Who’s eligible to participate in the class action?
Investors who acquired shares of Agenus Inc. between January 23, 2023, and July 17, 2024, can join the class action.
What should I do if I want to join the class action?
Reach out to the Rosen Law Firm for advice, or submit your details through their website.
What are the advantages of joining the class action?
By participating, you may have the chance to claim compensation with no upfront legal fees, depending on the case's outcome.
Why is the Rosen Law Firm a good choice?
The firm boasts a strong history in securities class actions and has achieved significant settlements for investors.
